What is Overall Survival or OS?
Overall Survival or OS IS a key measure in clinical trials.
Entries by DrUKM
What are RAS oncogenes?
RAS is a family of proteins which stay upstream of a cell signalling process
What are Small Molecule drugs?
As opposed to a biologic like a monoclonal antibody, a small molecule drug is an organic non-biologic drug with low molecular weight.
What is a Complete Response Letter or CRL?
A sponsor of a drug receives a CRL or Complete Response Letter from the FDA when the FDA needs to tell the sponsor that the NDA is unacceptable
Strategy – GILD
Down but not out. HCV, HIV pipeline still generating billions. Just need to go buy some decent company like it once did with Pharmasset.
Profile – BIIB
Biogen Inc., incorporated on April 1, 1997, is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis […]
Profile – GILD
Gilead Sciences, Inc., incorporated on June 22, 1987, is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B […]
Regeneron and Sanofi’s dupilumab shows significant treatment benefit in late-stage dermatitis study
Results from a Phase 3 clinical trial, CHRONOS, evaluating Regeneron Pharmaceuticals (REGN -0.1%) and Sanofi's (SNY -1.4%) DUPIXENT (dupilumab), in combination with topical corticosteroids (TCS), in patients with uncontrolled moderate-to-severe atopic dermatitis (AD) showed a significant treatment benefit compared TCS alone. The data will be presented today at the Annual Meeting of the American Academy […]
Prescriptions jump for EpiPen alternatives
Concerns over the soaring cost of Mylan's (NASDAQ:MYL) EpiPen, plus increased competition, appear to have taken a toll on sales of the brand-name allergy shot. Data from the Athenahealth network shows that prescriptions for EpiPen alternatives have quadrupled since the beginning of 2017. Put another way, the brand-name product's market share has fallen from around […]